pp-051.2 Tablets, immediate release (IR)
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
For chronic low back pain and chronic neuropathic pain.
Phase 2 development. Small-molecule analgesic;
Dual NOP/MOP receptor agonist engaging nociceptin and µ-opioid receptors. This first-in-class mechanism is designed to provide potent analgesia while reducing typical opioid-related risks.
Route / form: Oral immediate-release (IR) tablet.
Differentiation: Offers sustained analgesia for chronic pain conditions with a potentially safer profile than traditional opioids, including reduced abuse liability and improved long-term tolerability. Suitable for long-duration pain management where classical opioids pose safety concerns.
Manufacturer #18873
A privately-held, mid-size biopharma firm focused on developing and marketing therapies for ADHD, pain, addiction and CNS disorders. It combines proprietary drug-delivery technology with global development and licensing efforts to deliver patient-friendly medications worldwide.
Manufacturer usually replies in 45 days